Division of Critical Care, The George Institute for Global Health
Newtown, New South Wales, 2042, Australia
NCT Number: NCT04567433
We will perform a retrospective cohort study to assess the construct validity and performance of days alive and out of hospital at day 90 (DAOH90) in cohorts of patients with sepsis and septic shock who have been included in recent clinical trials.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Newtown, New South Wales, 2042, Australia
Study Design
We will conduct a retrospective cohort study. After obtaining all required ethics approvals, we will obtain data from the ARISE, CHEST, and ADRENAL studies. We will obtain from each dataset, for each trial participant with sepsis, data regarding; Demographic details, co-morbidities, pre-morbid living situation, baseline severity of illness, receipt of and duration of organ support during the index hospitalisation, Duration of ICU stay during index hospitalisation, ICU mortality, Hospital length of stay (LOS) and mortality for index hospitalisation, Discharge destination from index hospitalisation, readmissions to hospital up to 2 years, long term mortality, and quality of life as measured by the EQ5D at longest follow-up.
The primary objective of the study is to assess the association between Days Alive and Out of Hospital at day 90 and longer-term quality of life as measured by the EQ5D.
Secondary objectives include:
Sensitivity analysis For the primary analysis we will calculate the Days Alive and Out of Hospital with DAOH=0 for all patients who die prior to day 90, regardless of whether the death occurred in hospital or subsequent to discharge.
We will conduct a sensitivity analysis with Days Alive and Out of Hospital = the number of days alive and out of hospital prior to death. For example of a patient had a one week hospital admission and then spent 5 days at home prior to death the number of days alive and out of hospital = 5.
We will conduct a subgroup analysis based on:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Hydroxyethyl starch compared to 0.9% saline
Hydrocortisone compared to Placebo
Early Goal Directed Therapy compared to Usual Care
Time frame: 6 months
Quality of Life as measured by the EQ5D
The George Institute for Global Health, Australia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07658014
Cardiovascular Diseases, Infections
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05194189
Infections, Inflammation
Guanzhou, Guangdong, China
View Trial DetailsNCT07565649
Infections, Inflammation
Pamplona, Navarre, Spain
View Trial Details